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Abstract: Impaired language function is a principle criterion for the diagnosis of autism. The present 
study of brain from age-matched autistic and control subjects compared brain regions associated with 
the production and processing of speech. Wernicke's area (Brodmann 22, speech recognition), Broca's 
area (Brodmann 44, speech production) andthe gyrus angularis (Brodmann 39, reading) from autistic 
subjects (7-44 years of age) and control subjects (8-56 years of age) were examined microscopically. 
Striking differences in the density of glial cells, the density of neurons andthe number of lipofuscin-
containing neurons were observed in the autistic group compared with the control group. The mean 
density of glial cells was greater in the autistic cohort than controls in area 22 (p<0.001), area 39 
(p<0.01) andarea 44 (p<0.05). The density of neurons was lesser in autism in area 22 (p<0.01) and area 
39 (p<0.01). The autistic group exhibited significantly greater numbers of lipofuscin-containing cells 
in area 22 (p<0.001) and area 39 (p<0.01). The results are consistent with accelerated neuronal death in 
association with gliosis and lipofuscin accumulation in autism after age seven. Production of lipofuscin 
(a matrix of oxidized lipid and cross-linked protein more commonly associated with neurodegenerative 
disease) is accelerated under conditions of oxidative stress. Area 22 in autism evidenced the greatest 
glial increase, the greatest neuronal decrease andthe greatest increase of non-specific cells containing 
lipofuscin, which itself may contribute to greater free-radical generation in brain.  
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INTRODUCTION 
 
  Autism, a developmental neuropsychiatric disease, 
is diagnosed in early childhood and features social and 
communication  deficits,  restricted  and  repetitive 
behaviors  and  interests  anda  characteristic  course
[1]. 
Relatives of autistic subjects are more likely to manifest 
social, cognitive andpsychiatric deficits
[2-4] anda milder 
form  of  autism  is  unassociated  with  mental 
retardation
[5]. It is strongly suggested that outside the 
formal diagnosis of autism, there exists an unexpectedly 
large population with milder, but significant, social and 
communication deficits
[6]. 
  While  functional  alterations  in  cortical  auditory 
and  language  processing  in  autism  are  reported
[7], 
language-related cortex of autistic subjects has not been 
subjected  to  systematic  microscopic  examination. 
Language  is  a  complex  brain  function,  involving 
numerous subcortical and cortical areas, including areas 
for primary and secondary auditory processing. For this 
study  we  analyzed  three  higher-order  cortical  areas 
involved in the processing of language and production 
of speech: Wernicke's area, Broca's area and the angular 
gyrus in the brains from autistic and control subjects. 
  Wernicke's  area  (Brodmann  area  22)  is  a 
supplementary-auditory section of neocortex in the left 
temporal  lobe  which  mediates  the  understanding  of 
auditory  words.  Wernicke's  aphasia,  an  inability  to 
decipher  the  meanings  of  the  speech  sounds,  results 
from  damage  to  area  22.  Broca's  area  is  a  premotor 
region of the neocortex located in the left frontal lobe 
(Brodmann  areas  44  and  45)  which  mediates  the 
production and control of human speech. Lesions to this 
area (Broca's aphasia) produce speech problems, but do 
not  affect  semantic  or  basic  syntactic  abilities. 
Wernicke’s  and  Broca’s  areas  are  connected  by  the 
arcuate  fasciculus;  conscious  language  output 
originating in Wernicke’s area is carried via the arcuate 
fasciculus  to  Broca’s  area,  where  a  detailed  and 
coordinated program for vocalization is compiled and 
sent    to    the    facial  zone  of  the  motor  cortex.  The 
angular  gyrus  (Brodmann  area  39)  is  a  small  region 
behind Wernicke’s area which contains regions of the 
occipital, parietal andtemporal lobes. Area 39 facilitates  Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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interaction of visual and auditory brain cortex andhas 
been implicated in alexia, dyslexia
[8] and agraphia. 
  Hypothetically, structural alteration of one or more 
of  these  cortical  areas  might  contribute  to  the 
communication  impairment  found  in  autism.  The 
purpose  of  this  study  was  to  assess  the  microscopic 
anatomy  of  Wernicke's  area,  Broca's  area  andthe 
angular  gyrus  in  preserved  brain  of  accurately-
diagnosed  autistic  subjects  in  comparison  to  age-
matched  controls.  The  pattern  of  cortical  layering, 
relative  thickness  of  cortical  layers  andneuronal  and 
glial  densities  for  each  layer  was  determined.  Glial 
density,  neuronal  density  andnumber  of  nonspecific 
lipofuscin-containing  cells  was  determined  for  each 
subject. The data allowed assessment of each parameter 
as a function of subject age.  
 
MATERIALS AND METHODS 
 
Human subjects: The tissue required for this study was 
obtained  from  the  Harvard  Brain  Tissue  Resource 
Center, the Human Tissue Bank at the Universitiy of 
Miami  andthe  NICHD  Brain  and  Tissue  Bank  for 
Neurodevelopmental  Disorders  at  the  University  of 
Maryland, as facilitated by the Autism Tissue Program. 
Medical  history  and  documentation  of  autism  by 
Autism Diagnostic Interview (ADI-R) was provided for 
each subject. Formalin-preserved blocks from the left-
hemisphere were from eight autistic and seven control 
subjects: 
 
Autism      Control 
--------------------------------------------  ---------------------------------- 
Age  Sex   Identifier  Age  Sex  Identifier 
7  male  UMB-797  8  male  UMB-662 
9  male  B-4925  17  male  B-2234 
10  male  BTB-3714  22  male  B-4981 
14  male  B-4323  30  male  B-4211 
25  male  BTB-3711  46  male  B-4192 
26  male  B-5000  52  male  BTB-3692 
31  male  B-4871  56  male  B-4503 
44  male  B-4541   
 
Tissue  preparation:    Formalin-fixed  postmortem 
tissue blocks from areas 22, 39 and 44, were stored in 
10%  phosphate-buffered  formalin.  Portions  of  each 
block  were  immersed  in  20%  sucrose  cryoprotectant, 
then serially sectioned in perpendicular orientation to 
the pial surface with a sliding microtome, at 100 µm. 
Adjacent series of sections were stored at -20°C in a 
solution made of 3% glycerol, 3% ethylene glycol, 1% 
phosphate  buffer  (PB)  anddistilled  water;  alternate 
sections  were stained with cresyl violet (0.1%) in order 
 to visualize laminar boundaries. For lipofuscin study, 
sections  were  coverslipped  with  Fluoromount  G 
(Aname  17984-25).  All  sections  were  coded  and 
randomized  to  conform  with  strict  double-blind 
methodology.  
  Sample preparation for cell-counts involved several 
steps.  Blocks  were  divided  to  provide  a  portion  for 
microdissection  and  post-fixation  with  2%  OsO4  in 
0.9%  NaCl  containing  1.5%  potassium  ferrycianure 
(Sigma, St Louis, MO), for 1 h. Tissue was dehydrated 
with  propylene  oxide  and  flat-embedded  in  Epon;  1 
µm-thick sections were produced with a diamond knife, 
then  dried  on  glass  slides  andstained  with  basic 
toluidine blue (borate buffer, pH 11).  
 
Immunohistological staining: Astrocytes were stained 
with  polyclonal  antibody  to  glial  fibrillary  acidic 
protein (GFAP; DAKO, Denmark). The sections were 
rinsed  initially  with  TBS  (0.05  M  Tris  and0.15  M 
NaCl), pH 7.5, then pre-treated with a solution of 50% 
ethanol and 1% hydrogen peroxide (Sigma, St Louis, 
MO) in phosphate-buffered saline (PBS) for 30 min in 
order to remove endogenous peroxidase activity, then 
rinsed in PBS andsubsequently incubated in 1:5 normal 
goat serum for 30 min in order to block non-specific 
staining.  Then  primary  anti-GFAP  antibody  was 
applied at 1:200 dilution for 2 h at 4°C, followed by 
rinse  with PBS and incubation with biotinylated goat 
anti-mouse  antibody  1:200  in  PBS  for  1  h  at  room 
temperature  andsubsequent  processing  by  the  avidin-
biotin-peroxidase  method  (Vectastain  ABC 
immunoperoxidase kit: Vector, Burlingame, CA). DAB 
(3.3'-diaminobenzidine  tetrahydrochloride:  Sigma,  St 
Louis, MO) was used as the chromogen. Sections were 
mounted on glass slides, dehydrated, cleared in xylene 
and coverslipped. 
 
Morphometric  analyses:    An  optical  fractionation 
method  was  employed  to  estimate  cell  density.  This 
procedure is based on a random systematic choice of 
cortical  tissue  samples  andperformed  by  means  of  a 
regular,  previously-designed  grid  of  counting  frames 
(100×100 µm). An average of 4 fields per cortical layer 
was counted in each section, resulting in an average of 
24 fields for each sample in every cortical area studied. 
The cells were counted only if their somata fell entirely 
within the frame area. Cell density was calculated by 
dividing the total number of cells in each layer by the 
surface  area  of  the  frame  (or  in  the  examination  of 
cortical  colums,  division  by  the  area  of  the  cortical 
column). These data were expressed as number of cells 
per mm
2. Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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  The  randomized  and  codified  sections  were 
observed  with a 100× oil immersion lens on a  Leica 
DMRB  light  microscope.  200  µm-wide  columns, 
spanning  pia  to  white  matter,  were  examined  and 
plotted on paper with respect to cortical layers. Neurons 
and glial cells  were distinguished carefully. Neurons-
usually,  but  not  always  larger  than  glial  cells  were 
distinguishable  by  their  non-spherical  shape,  stained 
cytoplasm andvisible nucleolus. In contrast, glial cells 
were identified by the absence of cytoplasmic staining, 
small size andround shape.  
  Thickness of the cortical mantle was assessed with 
a Leica PL FLUOTAR lens, A.N. 0.12, which was used 
to represent a column through the entire extent of the 
cortical  mantle  on  graph  paper.  The  total  cortical 
thickness was noted to vary noticeably among different 
regions of a given cortical area, thus precluding direct 
comparisons  of  absolute  values.  Hence,  cortical 
thickness  was reported as percentage of total cortical 
thickness.  
 
Lipofuscin  identification  and  quantification:  
Lipofuscin-containing cells are readily  identifiable by 
autofluorescence.  A  Zeiss  III  RS  fluorescence 
microscope  with  an  HBO  50W  AC  super  pressure 
mercury lamp was utilized for determination of number 
of  cells  containing  lipofuscin.  Both  365  and  450  nm 
excitation  filters  were  employed  andcell  counts  and 
cell-density calculations were performed as previously 
described for glial and neuronal cells.  
  Reproduceable  photographs  of  intracytoplasmic 
lipofuscin  aggregates  were  obtained  using  a  confocal 
laser-scanning  microscope  (Leica  TCS  SL)  equipped 
with a Hellion/Neon laser and a 60×oil objective (Leica 
Plan Apochromat). The tissue sections were excited at 
488  and  568  nm  wavelengths  andthe  image  was 
reconstructed from a stack of 10 consecutive confocal 
planes. 
  Quantitative  analysis  of  the  size  of  the 
intracytoplasmic  lipofuscin  aggregates  was  performed 
on  single  optical  images  for  each  brain  section.  By 
employing  a  60×oil  lens  in  a  random-systematic 
manner,  a  region  of  interest  (ROI)  was  selected  by 
computer andaligned over layer I. The sampling ROI 
was  moved  vertically  through  all  cortical  layers 
andevery  deposit  of  lipofuscin  contained  within  the 
select  ROI  was  outlined  with  a  mouse  cursor.  The 
quantification of the lipofuscin area was accomplished 
with an Image Analysis System (Soft Imaging System 
GmbH, Münster, Germany) program.  
 
Statistical  analysis:    Cell  counts  across  hexalaminar 
cortical  columns  were  obtained  in  an  uninterrupted 
series of counting boxes that spanned the entire depth 
of cortex from the pial surface to the underlying white 
matter. Four distinct cortical probes were obtained for 
each  brain  area.  The  cell  density  for  each  case  was 
determined by dividing the number of cells counted in 
each sample by the total area of the chosen region. The 
data were expressed as the Mean±SD of the sample. 
  The statistical Student’s t-test was used to compare 
the  mean  values  from  individual  morphometric 
parameters  between  autistic  and  control  subjects  of 
matching ages. The confounding potential influence of 
postmortem delay andfixation interval were evaluated 
using the analysis of covariance,  which demonstrated 
no significant relationship.  
 
RESULTS 
 
Analysis of cortical laminar thickness: The thickness 
of cortical layers in relation to total cortical thickness in 
the three brain areas examined were not significantly 
different between autistic and control cohorts (Table 1).  
  
Longitudinal analysis of control data: 
Density of glial cells: In controls, the density of glial 
cells in full-depth cortical sections increased in all three 
brain areas as a function of age (Fig. 1a-c). Thus, in 
each brain area, glial density was approximately twice 
as  high  in  sixth-decade  subjects,  as  compared  to  the 
youngest subject, age 8. A steep rise in glial cells was 
measured in area 39 at age 30 (p = 0.0212) and in area 
44 at age 30 (p = 0.0007) (Fig. 2a-c). Generally, the 
decrement  in  glial  density  was  most  pronounced  in 
layers III, V and IV (Table 2).  
 
Neuronal density: In controls, a significant decline in 
neuronal  density  was  evident  in  full-depth  cortical 
sections   of   area   22  (by   40% from age 8 to age 56, 
p  =  0.0187),  but  not  in  area  39  or  44  (Fig.  2d,e.f) 
Laminar  analysis  (Table  3)  demonstrated  age-related 
declines   in   all cortical layers of area 22, particularly 
in   layers   II   (reduced   40%   from   age   8 to age 56, 
p = 0.0025)   and  IV  (reduced   35% from age 8 to 56, 
p = 0.0058). In area 39, a pronounced decrement was 
observed in layer V (50% from age 8 to 56, p = 0.0057) 
and  in  area  44,  there  was  a  moderate  decline  in 
neuronal density in layers II (reduced 21% from age 8 
to age 56, p = 0.0363). 
 
Lipofuscin-containing cells: The lipofuscin cell-count 
(Table 4)  did  not  differentiate  between   neuronal and Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Table 1:. Percentage of total cortical thickness. %: percentage. SD: standard deviation 
   Control               Autism 
   -------------------------------------------------------------------------  ---------------------------------------------------------------------------- 
    8  17  22  30  46  52  56  7  9  10  14  25  31  44 
I  %  8.66  6.57  7.57  8.35  6.02  7.67  7.52  9.93  10.51  7.77  10.65  7.06  7.14  7.02 
  SD  2.42  1.22  0.35  0.85  1.32  1.15  0.67  3.92  1.35  1.22  1.53  0.74  1.39  1.91 
II  %  5.73  7.19  7.31  6.44  7.38  7.48  6.62  7.29  7.67  6.63  8.33  6.10  7.25  6.23 
  SD  1.45  1.55  0.59  1.19  1.88  0.58  0.48  2.10  2.04  0.97  1.96  1.30  1.58  0.93 
III  %  25.71  25.14  31.28  27.35  28.10  40.89  32.64  41.65  40.34  38.47  37.99  31.25  37.01  29.36 
  SD  5.66  2.11  0.97  8.68  6.74  2.03  3.36  9.61  2.26  0.76  5.50  8.00  1.83  5.42 
IV  %  9.56  10.19  10.35  8.30  7.31  10.76  9.29  8.18  7.85  7.35  8.58  8.10  7.17  8.60 
  SD  1.33  1.54  2.46  1.75  0.92  3.50  1.12  1.44  1.08  1.21  1.71  0.80  1.07  0.91 
V  %  27.49  22.50  21.19  23.22  26.16  16.52  19.31  15.90  18.41  22.11  18.74  23.66  23.07  27.69 
  SD  3.71  3.40  3.96  5.96  5.37  4.22  2.23  4.75  2.78  2.72  2.15  3.19  5.37  7.27 
VI  %  22.86  28.41  22.29  26.34  25.03  16.68  24.63  17.04  15.23  17.68  15.70  23.84  18.37  21.11 
  SD  6.07  9.11  5.43  6.55  2.96  2.35  2.93  8.56  2.50  2.93  5.37  7.01  3.22  2.87 
I  %  9.59  10.45  10.20  5.48    10.70  11.29  8.81  12.16  7.32  11.44  6.23  8.45  8.20 
  SD  1.23  2.01  1.56  0.97    1.07  1.93  1.26  1.63  0.84  1.22  0.36  1.11  0.75 
II  %  8.22  10.45  14.58  6.85    6.73  11.29  6.85  10.81  6.10  9.80  6.23  8.45  6.56 
  SD  0.46  0.29  1.98  0.45    0.85  1.65  0.45  1.01  0.85  0.22  0.48  0.33  0.18 
III  %  36.99  26.87  34.99  30.14    33.64  38.71  33.86  37.84  29.27  37.58  28.35  36.62  31.15 
  SD  3.56  1.23  2.63  7.60    2.33  4.95  1.27  2.00  5.49  3.27  2.10  3.89  1.25 
IV  %  9.59  8.96  9.62  5.48    9.79  8.06  9.78  9.46  9.76  10.46  7.79  8.45  9.84 
  SD  0.99  1.00  0.49  0.13    0.36  1.08  0.85  0.44  0.34  1.22  0.17  0.75  0.61 
V  %  20.55  25.37  21.87  38.36    23.85  17.74  27.40  18.92  34.15  24.18  37.38  28.17  29.51 
  SD  2.34  2.45  1.12  5.47    2.37  1.20  5.11  2.10  5.22  3.11  1.27  2.33  1.52 
VI  %  15.07  17.91  8.75  13.70    15.29  12.90  13.31  10.81  13.41  6.54  14.02  9.86  14.75 
  SD  5.77  6.21  2.50  2.36    1.57  3.98  1.87  1.99  2.56  1.32  2.87  2.33  3.22 
I  %  9.00    10.69  10.29  6.47  7.62  8.02  5.59  8.88  6.27  7.33  7.69  8.49  8.14 
  SD  2.99    4.42  1.12  1.29  2.33  1.10  1.11  2.29  1.57  0.48  0.70  1.85  1.25 
II  %  7.16    6.07  7.23  4.63  4.88  5.41  4.70  4.77  6.42  4.99  5.07  5.18  3.90 
  SD  0.88    3.33  1.21  0.51  0.46  1.09  0.93  0.70  0.57  1.83  1.00  1.01  0.51 
III  %  28.21    30.47  21.76  25.62  29.50  33.13  24.37  21.71  23.87  21.51  26.33  31.94  29.48 
  SD  8.72    5.04  4.83  2.58  4.87  4.36  3.53  4.68  1.43  2.35  3.44  4.08  3.19 
IV  %  6.12    5.98  7.75  6.44  11.86  6.16  6.48  7.13  7.61  6.88  8.16  7.41  5.43 
  SD  0.90    1.34  1.89  1.07  8.10  0.49  0.73  0.96  0.83  1.99  1.44  1.47  1.76 
V  %  21.60    19.00  25.79  25.62  24.96  22.47  28.25  27.19  33.51  28.97  28.47  22.60  24.50 
  SD  6.12    9.11  7.91  3.26  7.81  4.43  1.94  1.75  3.45  5.09  3.79  2.71  3.49 
VI  %  27.90    27.79  27.19  31.22  21.18  24.81  30.62  30.32  22.32  30.31  24.27  24.37  28.55 
  SD  6.22    8.12  6.54  0.92  14.84  1.84  2.40  5.06  3.06  9.49  1.46  4.52  8.79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1:  Photomicrographs  illustrating  neurons  and  glial  cells  using  Nissl  staining  from  Wernicke´s  (area  22).  
Control cases (A, B and C) contrast with autistic cases (D, E and F).  As expected with aging, the older 
control subject (C) demonstrated increased density of glial cells and decreased density of neurons.  The 
changes are accelerated in autism, including the cohort's youngest subject, age 7 (D) Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Fig. 2: Density of glial cells, density of neurons, and density of lipofuscin-containing cells in brain areas 22, 39 and 
44.  Glial cells (A, B and C), neurons (D, E and F), and cells with lipofuscin (G, H and I) were counted 
along complete cortical columns.  Values for controls subjects are graphed in black, for autistic subjects in 
gray.  The horizontal axes correspond to age in years of the subjects, and the vertical axes represent the 
number of cells  mm￿
2 Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Table 2:. Number of glial cells mm￿
2. M: Mean. SD: standard deviation. T: total cell density 
    Control                 Autism 
    -------------------------------------------------------------------------  -------------------------------------------------------------------------- 
￿ 8  17  22  30  46  52  56  7  9  10  14  25  26  31  44 
BA22 
I  M  106.00  94.00  75.00  19.00  56.00  6.00  6.00  94.00  25.00  26.00  63.00  13.00  38.00  6.00  0.00 
  SD  48.01  36.98  43.30  12.93  10.83  5.12  4.38  20.73  12.74  8.80  19.86  6.82  12.50  4.18  0.00 
II  M  969.00  944.00  794.00  525.00  825.00  606.00  594.00  400.00  350.00  331.00  431.00  450.00  619.00  375.00  369.00 
  SD  108.07  151.43  133.90  139.94  101.55  92.49  105.14  98.43  98.43  71.53  100.58  93.54  94.17  123.74  75.78 
III  M  419.00  431.00  406.00  350.00  463.00  475.00  394.00  338.00  250.00  188.00  356.00  275.00  244.00  281.00  206.00 
  DS  122.95  83.62  103.64  113.65  45.07  131.10  99.02  115.24  98.43  67.31  125.47  84.78  48.01  94.17  71.53 
IV  M  988.00  1031.00  888.00  588.00  1000.00  781.00  644.00  619.00  575.00  538.00  550.00  538.00  475.00  513.00  575.00 
  SD  108.25  103.64  150.52  131.50  177.06  144.02  124.22  103.64  107.53  83.85  138.07  96.01  81.01  103.83  101.55 
V  M  500.00  619.00  544.00  344.00  506.00  469.00  388.00  350.00  325.00  363.00  413.00  331.00  244.00  363.00  319.00 
  SD  140.31  165.24  121.67  106.80  113.71  103.64  112.50  110.40  106.07  112.50  147.37  125.47  20.73  73.95  106.62 
VI  M  406.00  369.00  350.00  250.00  317.00  319.00  281.00  338.00  294.00  250.00  269.00  306.00  288.00  256.00  188.00 
  SD  145.10  83.62  101.55  104.08  56.98  83.62  87.28  97.31  77.81  63.74  81.73  77.81  27.95  48.01  73.95 
T  M  590.00  572.00  550.00  488.00  481.00  359.00  364.00  465.00  333.00  279.00  330.00  350.00  293.00  318.00  286.00 
  SD  103.00  132.00  127.30  87.98  123.20  114.30  97.00  102.30  105.80  99.87  129.60  114.43  93.72  102.34  84.37 
BA39 
I  M  56.00  63.00  50.00  56.00    0.00  0.00  50.00  56.00  44.00  38.00  13.00    19.00  6.00 
  SD  20.73  27.95  17.68  32.48    0.00  0.00  17.68  27.24  20.73  21.65  8.68    10.83  2.50 
II  M  907.00  975.00  943.00  821.00    721.00  693.00  893.00  407.00  421.00  557.00  514.00    636.00  429.00 
  SD  210.93  166.77  155.12  115.07    144.02  135.06  183.62  108.07  107.02  180.04  107.53    137.17  97.90 
III  M  513.00  431.00  425.00  438.00    325.00  331.00  544.00  306.00  350.00  444.00  400.00    394.00  225.00 
  SD  123.11  170.82  138.07  100.78    107.53  120.38  99.02  110.93  118.59  149.35  91.86    99.02  39.53 
IV  M  1050.00  994.00 1013.00 1019.00    994.00  956.00  756.00  500.00  581.00  756.00  663.00    813.00  606.00 
  SD  131.10  130.35  162.50  75.78    136.22  119.08  116.42  101.55  139.61  110.93  83.85    117.76  125.47 
V  M  531.00  531.00  481.00  425.00    250.00  238.00  431.00  331.00  325.00  338.00  325.00    313.00  294.00 
  SD  103.64  146.18  146.18  91.86    64.58  93.83  87.34  109.51  136.93  132.88  88.07    143.07  75.78 
VI  M  378.00  361.00  350.00  294.00    261.00  269.00  438.00  294.00  238.00  269.00  313.00    306.00  300.00 
  SD  87.40  72.93  108.07  99.02    127.93  54.13  97.63  89.05  73.95  83.62  73.95    99.02  93.54 
T  M  503.00  497.00  491.00  465.00    448.00  435.00  500.00  307.00  331.00  404.00  363.00    386.00  283.00 
  SD  104.10  76.23  132.47  109.98    83.79  103.81  103.30  88.79  122.37  118.92  79.87    122.20  75.40 
BA44 
I  M  144.00  106.00  25.00  113.00  38.00  44.00  81.00  156.00  63.00  69.00  75.00  13.00  38.00  58.00  56.00 
  SD  55.43  30.73  17.68  21.65  7.50  10.73  10.98  47.24  27.95  24.13  25.00  9.65  8.00  27.24  20.73 
II  M  806.00  606.00  644.00  713.00  550.00  731.00  638.00  800.00  581.00  688.00  681.00  669.00  531.00  563.00  463.00 
  SD  89.85  140.73  90.79  67.31  30.62  83.62  87.50  146.84  83.62  94.37  74.13  44.63  66.98  76.03  82.50 
III  M  350.00  294.00  306.00  350.00  306.00  300.00  338.00  306.00  263.00  225.00  388.00  300.00  256.00  306.00  238.00 
  SD  82.87  72.24  84.01  71.68  80.73  93.53  72.95  71.53  37.50  71.68  80.04  58.63  56.94  63.98  51.54 
IV  M  638.00  719.00  575.00  619.00  638.00  544.00  569.00  731.00  638.00  606.00  719.00  581.00  550.00  600.00  525.00 
  SD  110.87  127.93  68.47  63.98  62.50  56.94  63.98  76.94  67.31  62.19  72.24  73.69  77.06  84.78  88.39 
V  M  344.00  313.00  356.00  288.00  338.00  244.00  288.00  419.00  281.00  344.00  356.00  306.00  275.00  394.00  269.00 
  SD  82.60  57.28  48.01  62.50  54.07  73.69  72.95  72.24  60.42  110.93  77.81  73.69  55.90  63.98  44.63 
VI  M  319.00  281.00  394.00  219.00  175.00  288.00  244.00  269.00  238.00  265.00  225.00  188.00  231.00  219.00  188.00 
  SD  73.94  36.98  71.53  56.94  46.77  27.95  59.62  36.98  54.49  20.73  53.03  45.07  54.13  48.01  62.50 
T  M  316.00  310.00  341.00  321.00  315.00  317.00  313.00  390.00  290.00  303.00  298.00  305.00  327.00  340.00  281.00 
  SD  55.24  67.50  40.85  53.45  32.14  44.26  87.60  37.92  22.15  65.89  35.20  32.23  63.58  43.56  43.12 
 
glial  cells.  In  controls,  the  number  of  lipofuscin-
containing cells in full-depth cortical samples increased 
in  all  three  brain  areas from age 8 to age 56 in area 
22  by  770% (p   =   0.0015);    area    39    by    430% 
(p = 0.0001); and from age 8 to age 46 in area 44 by 
189%  (p  =  0.0001).  At  corresponding  ages,  the 
lipofuscin cell-count was consistently higher in area 44 
than  in  areas  22  or  39  (Fig.  2g-i).  Laminar  analysis 
demonstrated greatest gross number of cells containing 
lipofuscin  in  layers  II  and  IV,  layers  with  high  cell 
density. Qualitatively, the size of individual lipofuscin 
aggregates appeared greatest in layers III and V, also 
the site of largest pyramidal cells (Fig. 3).  
 
Longitudinal analysis of autism data 
Density of glial cells: In the autistic cohort, the density 
of  glial  cells  (Table  2)  in  full-depth  cortical  sections 
increased significantly over time in area 22 (89% from 
age 7 to age 44, p = 0.0061) and in area 39 (66% from 
age  7   to  age   44,  p = 0.0012), but not in area 44 Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Fig. 3:  Photomicrographs  illustrating  intracytoplasmic  deposits  of  lipofuscin  (arrows)  in  toluidine  blue-stained 
semi-thin sections. The size of individual lipofuscin aggregates in the cerebral cortex of 17-year-old autistic 
subjects (B and D) are similar to those in the 52-year-old control subject (A and C) 
 
(Fig. 2a-c). A steep rise in density of glial cells in area 
22  between  age  7  and  10  (42%)  was  statistically 
significant (p = 0.0424) andfollowed by a plateau from 
age 10 to age 31.  
  Laminar  analysis  (Table  2)  demonstrated 
statistically significant increase in density of glial cells 
in all layers of area 22; the least increase from age 7 to 
age 44 was seen in layer V and VI (48%, p = 0.0080; 
65%, p = 0.0040). Although full-depth cortical sections 
did not demonstrate statistically-significant age-related 
changes  in  glial  density,  significant  increases  were 
found in layer III of area 39 (136% from age 7 to age 
44, p = 0.0026) and layers IV and V of area 44 (97% 
increase from age 7 to age 44, p = 0.0041; 93% increase 
from age 7 to age 44, p =   0.0005).  
 
Neuronal  density:  In  the  autistic  cohort,  decreased 
density  of  neurons  over  time  in  full-depth  cortical 
samples  was  evident  in  all  three  brain  areas,  with  a 
steep  early  decline  followed  by  essential  plateau  in 
density  of  neurons  no  later  than  age  10  (Fig.  1d-f). 
From age 7 to age 44, density of neurons decreased in 
area 22 by 39% (p  =  0.0324), in area 39 by 43% (p  =  
0.0144) and in area 44 by 30% (p  =  0.0090). The most 
pronounced decrease in neuronal density from age 7 to 
age 44 in area 22 was layer VI (39%, p  =  0.0351), in 
area 39, layer II (57%, p  =  0.0042) andin area 44, 
layer II (42%, p  =  0.007) (Table 3).  
 
Lipofuscin-containing cells: In full-thickness cortical 
samples  from  autistic  subjects,  the  number  of 
lipofuscin-containing  cells  increased  over  time  in  all 
three areas of brain. Pronounced increases were found 
between age 7 and age 14 in area 22 (69%, p  =  0.014), 
area   39   (149%,   p  =  0.0002)   and    area   44 (45%, 
p    =    0.002)  (Fig.  2g-i).  In  this  younger  subset,  the 
range of lipofuscin-containing cells was 180 cells mm￿
2 
in  area  22,  226  cells  mm￿
2  in  area  39  and  690  cell 
mm￿
2 in area 44 (Table 4). 
 
Transversal  analysis:  Comparison  of  autistic  versus 
control subjects. Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Table 3:  Number of glial cells  mm￿
2. M: Mean. SD: standard deviation. T: total cell density 
    Control               Autism 
    --------------------------------------------------------------------  ------------------------------------------------------------------------------------ 
  ￿ ￿ ￿   8  17  22  30  46  52  56  7  9  10  14  25  26  31  44 
BA22 
I  M  592  516  708  1000  992  1108  1141  916  975  942  817  1083  1050  842  1150 
  SD  103.75  116.67  89.37  247.95  82.92  75.92  86.20  153.66  132.02  134.11  144.34  151.84  158.99  138.19  121.34 
II  M  558  608  642  674  825  1209  1155  800  1200  1242  1400  1200  875  1267  1630 
  SD  118.73  125.55  147.90  211.48  121.05  123.32  192.03  197.20  154.56  138.19  131.23  158.11  147.90  187.08  174.80 
III  M  491  350  430  475  817  967  992  717  758  1033  1258  983  824  1166  1434 
  SD  168.94  98.60 131.23  170.78  121.34  224.85  190.58  178.73  173.81  227.30  173.81  186.34  103.75  187.08  217.31 
IV  M  567  534  608  776  1133  1234  1283  992  1084  1316  1442  1217  1133  1750  1825 
  SD  108.01  147.20  147.90  170.78  124.72  222.36  153.66  176.97  167.50  167.50  125.55  128.02  179.51  222.98  209.99 
V  M  467  459  675  917  1119  1108  1192  1058  1040  1163  1175  1059  1108  1225  1575 
  SD  110.55  125.55  178.54  189.54  158.77  243.10  216.51  155.23  220.32  222.05  240.80  217.79  116.37  236.14  215.22 
VI  M  475  283  475  1025  1167  1140  1217  792  1192  1192  1184  1108  1091  1217  1308 
  SD  125.55  98.60 165.62  214.95  139.44  217.79  206.16  144.10  157.01  203.27  180.28  155.23  98.25  184.84  183.14 
T  M  560  488  622  704  978  1023  1077  863  1054  1229  1244  1311  1279  1287  1638 
  SD  134.63  152.37  136.76  153.81  198.22  201.00  243.20  216.13  243.87  186.56  223.62  265.92  267.88  237.68  306.55 
BA39 
I  M  508  467  608  808    1042  1133  658  892  867  667  1050    1158  1142 
  SD  64.01  113.04  125.55  111.49    180.08  200.00  95.38  72.17  108.01  40.82  128.02    180.08  144.10 
II  M  625  600  725  842    1058  1100  1067  1167  1325  875  1150    958  1017 
  SD  138.19  154.56  144.10  147.90    170.58  204.12  198.61  182.57  144.10  212.62  254.41    186.15  144.34 
III  M  475  367  575  758    992  1042  458  758  933  792  942    783  1092 
  SD  155.23  126.93  208.67  138.19    237.32  134.11  138.19  212.62  179.51  147.90  184.65    192.21  216.51 
IV  M  675  625  808  1008    1125  1117  917  1083  1208  1142  1242    1367  1450 
  SD  170.58  205.99  219.06  127.75    207.33  186.34  207.50  172.40  222.83  132.02  116.37    149.07  202.07 
V  M  650  467  633  992    1092  1058  767  1042  1033  958  1217    1042  1208 
  SD  144.34  143.37  184.09  168.94    222.83  217.79  187.08  254.27  181.05  200.52  232.74    249.86  175.40 
VI  M  683  442  592  792    1267  1283  892  1192  1275  1008  1142    875  1200 
  SD  121.34  116.37  151.61  178.54    190.03  172.40  157.01  200.52  153.43  147.90  212.62    181.62  197.20 
T  M  520  590  645  739    1163  1077  767  794  852  830  1066    1102  1277 
  SD  67.87  112.78  86.56  123.56    117.98  132.56  99.89  87.56  112.70  56.76  90.87    118.97  147.65 
BA44                              
I  M  592  525  508  944  887  927  1008  550  705  575  791  683  629  967  1105 
  SD  76.93  123.89  53.15  105.46  95.42  139.45  112.61  125.97  82.24  127.77  133.73  53.49  86.86  99.43  171.26 
II  M  558  708  685  677  879  750  1040  700  767  541  675  841  830  960  895 
  SD  107.90  75.65  66.01  51.00  102.30  92.30  129.79  183.90  114.05  83.42  185.83  121.94  76.93  92.30  100.40 
III  M  492  675  653  661  774  919  984  625  616  608  683  825  758  823  790 
  SD  66.50  132.02  117.14  95.42  102.01  130.04  133.98  73.47  103.98  69.84  47.71  83.42  117.42  108.20  141.53 
IV  M  567  733  710  798  960  968  1105  617  698  843  841  1108  1016  1274  1218 
  SD  52.88  144.94  60.35  112.61  160.28  197.54  141.30  103.28  93.51  95.08  129.79  61.94  86.86  123.91  246.07 
V  M  467  691  669  766  927  1153  1145  567  733  1008  916  1025  1024  1347  1097 
  SD  103.28  60.35  57.59  171.26  143.13  136.93  183.19  45.62  127.00  155.33  66.50  132.30  129.84  176.93  149.57 
VI  M  475  891  863  847  1387  1266  1185  1059  1008  1133  1226  1033  1073  1565  1137 
  SD  92.30  61.94  74.71  47.71  133.00  183.42  121.50  135.94  189.99  131.03  51.00  92.30  146.72  123.89  185.83 
T  M  540  835  796  817  965  960  973  901  819  738  852  1067  1023  981  1075 
  SD  35.87  56.29  98.27  78.68  101.27  91.09  104.64  101.09  65.20  74.00  63.91  108.86  125.68  86.49  127.44 
 
Density of glial cells: The density of glial cells in full-
thickness cortical samples was greater in autism than 
age-matched controls andthere  was  no intersection of 
plotted  curves.  Collectively,  samples  from  autistic 
subjects      evidenced  significantly  greater  density  of 
glial cells in area 22 (90%, p  =  0.0002), area 39 (40%, 
p  =  0.0032) andarea 44 (20%, p  =  0.0262). Greater 
mean  density  of  glial  cells  was  evident  in  autism 
compared to controls in all six cortical layers. Plotted 
curves  for  glial  density  demonstrated  an  approximate 
linear increase in control cohorts in all brain areas andin 
area  39  of  the  autistic  cohort.  For  subjects  of  age  7 
through 10, area 22 from autistic subjects evidenced a 
steep linear increase between age 7 and age 10, then 
plateau through age 26 andarea 44 of the autistic cohort 
demonstrated  a  linear  decline  (Fig.  2a-c).  Generally, 
laminar  glial  density  in  autistic  subjects  was  greater 
than  controls  of  corresponding  age,  although  no 
difference was found in layer IV (granular) andlayers II 
and III (supragranular) of area 44. It also was noted that 
the  autism-versus-control  difference  in  glial  density 
gradually diminshed between age 7 and age 31 in layers 
V and VI of area 44, while it increased in other layers 
(Table 2).  Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Table 4:  Number of cells containing lipofuscin/ mm
2. M: Mean. SD: standard deviation. T: total cell density 
    Control              Autism 
    ------------------------------------------------------------------------  -------------------------------------------------------------------------------- 
    8  17  22  30  46  52  56  7  9  10  14  25  31  44 
BA22 
I  M  105  177  323  556  677  1145  1202  89  460  411  790  702  758  1306 
  SD  42.50  63.06  104.52  145.08  150.00  349.19  463.71  50.81  129.84  123.39  96.77  227.42  272.58  516.94 
II  M  32  274  411  589  597  996  1105  52  427  435  621  839  702  1347 
  SD  17.74  99.55  143.31  207.82  301.61  542.98  439.52  49.19  114.52  108.87  237.90  397.58  244.35  451.61 
III  M  97  226  298  516  718  1097  1153  93  435  524  637  742  790  1137 
  SD  28.23  90.32  93.71  98.23  276.61  477.42  401.45  34.68  107.26  130.65  175.00  290.32  223.39  360.48 
IV  M  121  218  363  524  758  1395  1484  105  556  645  718  847  879  1444 
  SD  50.81  50.81  88.81  240.00  340.32  508.95  504.03  91.13  75.81  137.90  246.77  298.39  319.35  540.32 
V  M  129  298  419  556  694  1097  1089  153  524  565  589  790  815  1194 
  SD  64.52  102.30  129.84  219.35  340.32  446.77  376.29  51.61  115.32  107.26  195.97  260.48  297.58  427.42 
VI  M  153  202  379  492  871  984  1115  234  403  653  790  774  734  1226 
  SD  52.42  97.50  115.32  187.10  403.06  413.71  421.37  56.45  154.84  135.48  312.90  254.03  293.87  350.81 
T  M  134  373  464  576  1184  1124  1171  180  389  413  660  737  815  1525 
  SD  77.92  129.56  102.27  103.89  408.94  388.00  368.32  65.78  109.22  168.29  117.82  298.88  233.76  537.22 
BA39                               
I  M  65  153  290  492    1161  1169  210  355  362  597  863  898  1218 
  SD  23.21  63.49  49.70  189.20    234.20  202.56  75.40  67.80  98.60  93.20  125.40  119.20  29.30 
II  M  121  129  339  637    1185  1145  153  548  466  758  911  960  1234 
  SD  75.12  30.12  55.12  92.09    145.78  216.33  45.21  60.79  98.70  123.6  113.34  117.29  140.25 
III  M  153  218  274  677    1065  1121  169  387  492  605  944  935  1089 
  SD  69.72  73.29  70.73  156.90    198.89  198.99  34.98  64.33  60.08  86.75  113.34  145.80  121.31 
IV  M  145  153  339  718    1002  1387  177  476  540  621  1113  1105  1419 
  SD  79.23  53.40  119.56  105.37    249.60  257.30  90.34  98.78  67.89  105.80  123.23  239.06  148.34 
V  M  169  250  395  621    1008  1048  129  371  435  573  863  879  1161 
  SD  56.5  68.30  79.20  114.50    198.34  265.80  34.70  56.8  67.80  54.12  86.34  70.15  122.23 
VI  M  194  234  347  605    952  1032  177  395  371  613  895  911  1121 
  SD  67.8  91.10  64.98  107.30    113.20  199.20  33.09  66.08  54.98  78.90  111.21  177.14  109.23 
T  M  209  361  455  568    1034  1117  226  236  370  593  686  813  1456 
  SD  43.56  55.98  98.23  123.40    208.71  198.47  56.50  43.89  59.93  79.32  81.09  102.95  117.34 
BA44                               
I  M  234  796  786  1105  926      230  548    826  866  896  1204 
  SD  43.15  63.06  98.25  98.64  56.49      45.85  66.00    66.08  34.59  43.12  85.32 
II  M  234  577  707  617  956      321  498    518  796  1075  1154 
  SD  33.99  51.16  63.23  99.11  85.32      39.44  37.19    43.56  65.12  112.56  109.99 
III  M  332  478  478  697  796      388  548    677  806  816  736 
  SD  58.45  39.98  69.56  75.23  79.56      62.23  55.74    66.50  90.12  74.10  85.95 
IV  M  405  826  647  856  1025      678  587    956  1016  1264  1194 
  SD  64.12  67.78  63.94  78.06  99.87      56.98  69.33    87.28  99.20  123.56  132.56 
V  M  268  816  776  667  1224      508  558    786  876  1005  796 
  SD  68.01  112.32  78.92  56.36  103.56      36.87  55.37    82.71  96.32  112.09  53.94 
VI  M  310  856  796  866  1125      440  488    856  866  1006  846 
  SD  56.00  73.75  75.28  82.81  136.45      58.79  40.23    97.25  86.34  109.00  66.93 
T  M  477  1125  1026  1167  1379      690  866    1256  1108  1377  1288 
  SD  87.20  120.38  117.95  132.47  137.74      69.56  65.47    136.59  109.33  137.86  121.03 
 
Neuronal  density:  Mean  neuronal  densities  for  full-
thickness cortical samples were significantly reduced in 
the autistic cohort as compared to controls in area 22 
(38%  reduction,  p    =    0.0012)  and  area  39  (24% 
reduction, p  =  0.0011), but no significant difference 
was  found  in  area  44.  In  relation  to  controls, 
decrements in neuronal density were greatest in area 22. 
Values in autism were lower at all corresponding ages 
in  area  22  andall  but  age  7  in  area  39.  Steep  initial 
declines in neuronal density from age 7 to age 10 and 
essential      plateau  thereafter  in  areas  22  and  39  in 
autism  contrasted  with  gradual  linear  declines  in 
controls (Fig. 2d-f).  
  In area 22, the difference in neuronal density grew 
from 20% fewer neurons at age 10 (p  =  0.0132) to 
42%  fewer   neurons in adolescence (p  =  0.0395) 
(Fig.  2d).  The  greatest  difference  in  neuronal  cell 
density  in  area  22  was  evident  in  layers  II  and  IV 
(Table  3).  The  neuronal  density  in  area  39  for  the 
control  group  declined  very  little  with  increasing 
chronological  age.  Neuronal  density  in  area  39  was 
equivalent for the youngest autistic (age 7) and control 
(age 8) subjects. In area 39, a steep decline in neuronal 
density  was  evident  between  age  7  and  ages  9/10  in 
autism (34%; p  =  0.0282), but density in the eldest 
autistic  subject  (age  44),  was  not  substantially  lower 
than at ages 9/10 (Fig. 2e). Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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Fig. 4:  Photomicrographs illustrating glial cells using immunocytochemical staining methods for the glial fibrillary 
acidic protein (GFAP). A and B demonstrate protoplasmic astrocytes and C and D demonstrate fibrous 
astrocytes.  Conspicuous  alterations of   the   morphology of   the glial cells are evident in autistic patients 
(B and D), compared to control cases (A and C) 
 
Laminar  analysis  indicated  that  the  decrement  of 
neurons   evident in autism relative to controls at age 7 
in   area   22 was most pronounced in layers V or VI 
(the   infragranular   layer),  than   in  layers II or III 
(Table 3). By age 10, the neuronal density in layer II of 
area 22 in autism was 53% lower than corresponding 
control  (  p    =    0.0055).  In  area  44,  lower  neuronal 
density in autism versus controls was found primarily in 
cortical layers II and III in younger subjects; in older 
subjects, decrements relative to controls were found in 
nearly all layers (Table 3). 
 
Lipofuscin-containing cells: The density of lipofusin-
containing cells in full-thickness cortical samples was 
greater  in  the  autistic  cohort  than  controls:  area  22 
(50%   greater, p  =  0.0007) and area 39 (44% greater, 
p    =    0.0096).  Other  than  equivalent  values  for  the 
youngest of either cohort for areas 22 and 39, autistic 
subjects  showed  greater  density  of  lipofuscin-
containing cells than controls at all corresponding ages. 
The  youngest  (age  7  years)  member  of  the  autistic 
cohort  evidenced  greater  density  of  lipofuscin-
containing cells (46% greater, p  =  0.0086) in area 44 
than the corresponding 8-year-old control.  
  Relative to controls, the autistic group evidenced 
steep increases in the density of lipofuscin-containing 
cells   between age 7 and 14 in all three brain areas. 
(Fig.  2g-i)  For  instance,  the  density  of  cells  with 
lipofuscin in area 22 in autistic subjects of age 9/10 was 
equivalent to density in the control subject of age 17; by 
age  14,  the  density  of  cells  containing  lipofuscin  in 
autism were approximately twice the density in control 
subject of age 17. (p< 0.0168) (Fig. 2g). Similar sharp 
rises  were  apparent  among  younger  members  of  the 
autistic cohort in areas 39 and 44. However, significant 
increases were not observed in area 44 in autism after 
age 10 (Table 4). 
  Laminar analysis demonstrated greater density of 
lipofuscin-containing cells particularly in layers II and 
IV in all three areas of brain (Table 4). Microscopic Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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observation  imparted  the  impression  that  larger 
lipofuscin aggregates were more concentrated in layers 
III and V in areas 22 and 39. 
Morphological  analysis  of  glial  cells:    Variant 
astrocyte  morphology  was  observed  in  autism.  In 
comparison  to  controls,  both  the  subclass  of 
protoplasmic astrocytes (characterized by short, thick, 
highly-branched processes) and the subclass of fibrous 
astrocytes  (characterized  by  long,  thin,  less  branched 
processes)  demonstrated  earlier  hypertrophy  of  the 
perikaryon and processes in autism. (Fig. 4a-d) Further, 
the subclass of protoplasmic astrocytes exhibited larger 
size,  denser  ramification  of  fine  processes  anda 
fibrinoid aspect in austim that was not appreciated in 
control specimens (Fig. 4b). 
 
DISCUSSION 
 
  The  present  autism  study  constitutes  the  first 
neuroanatomical  analysis  of  diverse  regions  of  the 
cerebral  cortex  involved  in  linguistic  processing  and 
production  of  speech,  across  a  broad  age-group. 
Autistic cortex was markedly altered in comparison to 
age-matched  controls,  including  increased  density  of 
glial cells, decreased density of neurons andincreased 
density of nonspecifc lipofuscin-containing cells.  
  Previous  reports  suggest  neurodevelopmental 
aberration  in  autism.  Kemper  and  Bauman  (1993) 
reported a coarse and poorly-laminated cingulate cortex 
in  autism  andother  authors  have  presented  functional 
evidence of abnormal connections, as well as a delay in 
the maturation of some cortical circuits 
[9-12]. Positron 
Emission Tomography (PET) and Magnetic Resonance 
Imaging  (MRI)  scans  of  autistic  subjects  suggest 
cortical  ectopias,  a  distinctive  feature  of  altered 
neuronal migration
[10, 13-15].  
  The present study found no deviation from normal 
cortical layering pattern, evidence of ectopic cells, nor 
differences in the relative thickness of cortical layers in 
areas 22, 39 and 44 of brain from autistic subjects. If 
the  cytoarchitectonic  criteria  of  Benes
[16]  are  valid, 
these findings argue strongly against the hypothesis of 
altered neuronal migration in the neuropathogenesis of 
autism. 
 
Cortical   gliosis   in autism: In all three brain areas 
(22,  39  and  44),  full-thickness  cortical  samples  from 
autistic  subjects  of  all  ages  demonstrated  greater 
density of glial cells in comparison to controls (up to 
more than double). Since thickness of the cortical layers 
is not altered in autistic subjects, the finding of greater 
glial density in autism implies a greater gross number 
of glial cells in each area due to cellular proliferation 
andnot  due  to  reduction  of  neuropil  volume. 
Proliferation of glial cells as well as the hypertrophic 
morphological changes in glia reported in this study are 
consistent with reactive gliosis in autism. 
  Proliferation  of  glial  cells  occurs  in  diverse 
pathologies,  including  ischemia,  trauma, 
neurodegenerative  disorders  andsenescence
[17-22].  Glial 
fibrillary acidic protein (GFAP), a major intermediate 
structural filament protein expressed predominantly in 
mature astrocytes, is considered a hallmark of gliosis 
under  conditions  of  neuronal  injury
[23-25].  A  marked 
increase in the number of neuroglial cells in the middle 
frontal gyrus, anterior cingulate gyrus andcerebellum of 
autistic  patients,  as  well  as  increased  inflammatory 
cytokines in parenchyma and cerebrospinal fluid (CSF) 
have been reported in autism
[26]. Significantly elevated 
concentrations  of  GFAP  were  reported  in  the  CSF, 
frontal, parietal andcerebellar cortices of children with 
autism
[27,28].  The  results  of  the  present  study  present 
further evidence for widespread gliosis in autism. 
  A toxic etiology for autism has not been excluded. 
Many toxins induce gliosis,  including  metals  such as 
lead, iron andmercury, which specifically induce glial 
proliferation,  degeneration  anddecreased  cellular 
function  in  some  regions  of  the  brain
[29-33]. 
Neurotoxicity  of  metals  is  primarily  mediated  by 
increased  oxidative  stress  and  both  increased  metals 
and  increased  oxidative  stress  are  reported  in 
autism
[34,35]. Hypothetically, environmental exposure in 
sensitive subjects might underlie glial proliferation and 
neuronal death in the pathogenesis of autism.  
 
Neuronal attrition in autism: Other investigators have 
reported  reduced  numbers  of  neurons  (cerebellar 
Purkinje and granule cells)
[36-38,15] in brain of subjects 
with autism, but there are no prior reports of decreased 
neurons  in  cerebral  cortex.  Coleman
[39]  examined 
auditory brain regions, including Broca's area, from a 
single subject with a presumptive diagnosis of autism, 
but found no differences in neuronal density relative to 
control  subjects.  Magnetic  resonance  imaging  of 
autistic subjects of 3-4 years of age demonstrated less 
n-acetyl aspartate (NAA)
[40], a metabolite produced by 
neurons, but not glia.  
  The  present  study  employed  a  larger  cohort  of 
systematically  diagnosed  autistic  subjects  andfound  a 
striking reduction in neuronal density in area 22 and 39 
in autism relative to controls, including lower density of 
neurons in area 22 from the youngest member of the 
autistic cohort (age 7). Neuronal density in area 39 was 
equivalent in the youngest autistic subject and youngest 
control  (age  8),  suggesting  that  the  reduced  neuronal 
density in older autistic subjects is not explicable on the Am. J. Biochem. & Biotech., 4 (2): 130-145, 2008 
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basis  of  failed  genesis,  but  due  to  attrition.  Loss  of 
cortical  neurons  has  been  described  in  other 
neuropsychiatric  pathologies,  such  as  schizophrenia, 
bipolar  disorder  andmajor  depressive  disorder,  all  of 
which  coexist  with  different  cognitive  impairments, 
some similar to those observed in autism
[41-44].  
  Decrease in density of neurons in autism was most 
pronounced  in  cortical  layers  II  and  IV.  While  the 
present study did not separately tabulate pyramidal cells 
and  smaller  neurons,  its  findings  are  comparable  to 
decreased pyramidal cells in layers II and III and, less 
conspicuously,  in  layers  V  and  VI  in  frontal  and 
temporal  neocortex  in  Rett  syndrome 
[45],  a 
neurodegenerative disease associated with autism
[46-48]. 
The  relationship  of  increased  glial  cell  density  and 
decreased  neuronal  cell  density  varied  in  autism  by 
brain  area.  Increased  glial  density  coincided  with 
decreased neuronal numbers in area 22 and are 39, but 
not area 44. A significant increase in glial density in the 
youngest  member  of  the  autistic  cohort  (age  7)  was 
associated with decreased neuronal density in area 22, 
but not in area 39. Determination of glial and neuronal 
densities in a larger cohort including younger subjects 
is  needed  to  elucidate  the  temporal  and  functional 
relationship of these two parameters.  
 
Indications of oxidative stress in autism: One of the 
more  interesting  findings  of  the  present  study  is  the 
significant  increase  of  lipofuscin-containing  cells  in 
autism.  Lipofuscin  is  classically  associated  with 
recognized  neurodegenerative  diseases  andthere  is  no 
prior  record  of  previous  examination  of  brain  from 
autistic subjects for lipofuscin. Increased lipofuscin was 
reported previously in brain from subjects with Rett's 
syndrome 
[49-51]. 
  Lipofuscin is an intralysosomal polymeric material 
originated from autophagocytosed cellular components 
that  cannot  be  degraded  or  exocytosed.  Biochemical 
analysis of lipofuscin reveals a complex aggregated by-
product  composed  primarily  of  oxidatively-modified 
proteins  and  lipids
[52-55].  In  addition,  lipofuscin  is  a 
depot  for  metals,  including  redox-active  and  heavy 
metals
[56].  Lipofuscin  accumulation  in  cells  is 
accelerated  under  conditions  of  oxidative  stress
[57-59]. 
Experimentally, lipofuscin itself induces neurotoxicity 
via generation of free-radicals
[52-54].  
  Several authors have proposed the involvement of 
free  radicals  andcross-linking  reactions  by 
intralysosomal degradation products, as initial steps in 
the  formation  of  lipofuscin
[58,60,61].  Higher  levels  of 
lipofuscin may be viewed as a marker for heightened 
oxidative  processes  which  are  potentially  harmful  to 
brain cells
[52], or for greater oxidative damage to brain 
cells. 
  Extensive research has demonstrated that oxidative 
stress plays a seminal role in the pathology of several 
neurological  diseases,  including  Alzheimer’s 
disease
[62,63],  Down’s  syndrome
[64],  Parkinson’s 
disease
[65,66],  schizophrenia
[67,68]  andbipolar  affective 
disorder
[69]. Interestingly, recent studies have reported 
increased  free-radicals,  lower  levels  of  antioxidant 
proteins andgreater oxidatively modified biomolecules 
in peripheral samples from autistic children
[70-77]. 
  Significantly  increased  numbers  of  lipofuscin-
containing cells were found in the three brain areas of 
subjects with autism andwere most pronounced in area 
22,  which  also  featured  the  greatest  increase  in  glial 
density and greatest decrease in neuronal density. Since 
the lipofuscin cell-count did not differentiate  neurons 
and  glia,  the  profile  of  brain  cells  with  increased 
lipofuscin  in  autism  remains  undetermined.  As  noted 
earlier,  the  size  of  lipofuscin  aggregates  was  judged 
greatest in layers III and V in areas 22 ad 39, which is 
noted to be the cite of the largest pyramidal neurons. In 
one area (44), increased lipofuscin was evident in the 
youngest of the autistic cohort (age 7), suggesting that 
greater  lipofuscin  as  well  as  differential  glial  and 
neuronal densities may be detectable in younger autistic 
subjects in further studies.  
  The  data presented  are  strictly  phenomenological 
anddo  not  afford  firm  conclusions  about  mechanistic 
relationships  among  the  three  measured  parameters. 
While the study did not determine the extent of glial 
(versus  neuronal)  lipofusin  content,  it  is  known  that 
lipofusin  appears  in  reactive  glial  cells
[78]  andthat 
oxidative stress in glial cells alters their function
[79,80]. 
Greater   lipofuscin in brain of autistic subjects of age 
7-44 probably reflects greater oxidative stress in brain, 
as suggested by peripheral measurements of oxidative 
stress in autism
[70-72,81]. The increased numbers of cells 
containing  lipofuscin  may  reflect  (a)  an 
environmentally-induced  reactive  glial  response 
injurious  to  neurons,  (b)  an  environmentally-induced 
direct oxidative injury to neurons, or (c) both. 
  In summary, the present study of language-related 
cortical  areas  22,  39  and  44  demonstrated  a  greater 
density of glial cells, a lesser density of neurons andan 
increased density of non-specific lipofuscin-containing 
brain cells in autism. Changes in these parameters were 
progressive  andvaried  in  extent  by  cortical  area  and 
layer.  
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